Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

(2016) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Trece tratamientos de la insuficiencia renal aguda secundaria a mieloma múltiple con filtros de high cut off

(2016) Ana Berni Wennekers et al.   NEFROLOGIA

Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study

(2016) Hans U. Gerth et al.   PLoS One

Citrate Extended High Cut-Off Hemodiafiltration for Renal Recovery in Patients With Multiple Myeloma

(2016) Andreja Marn Pernat et al.   THERAPEUTIC APHERESIS AND DIALYSIS

Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment

(2015) Beatrice Anna Zannetti et al.   AMERICAN JOURNAL OF HEMATOLOGY

Plasmapheresis in cast nephropathy

(2015) François Madore   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

ESRD due to Multiple Myeloma in the United States, 2001-2010

(2015) S. Reule et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Diagnosis of monoclonal gammopathy of renal significance

(2015) Frank Bridoux et al.   KIDNEY INTERNATIONAL

Monoclonal gammopathy of renal significance: systemic involvement by benign condition

(2015) Vincenzo L'Imperio et al.   KIDNEY INTERNATIONAL

Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

(2015) Camille Cohen et al.   KIDNEY INTERNATIONAL

Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients

(2015) Laure Ecotière et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Effectiveness of Haemodiafiltration with Heat Sterilized High-Flux Polyphenylene HF Dialyzer in Reducing Free Light Chains in Patients with Myeloma Cast Nephropathy

(2015) Mathieu Rousseau-Gagnon et al.   PLoS One

Severe acute kidney injury and multiple myeloma: Evaluation of kidney and patient prognostic factors

(2014) Luís Rodrigues et al.   European Journal of Internal Medicine

A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR)

(2014) Sonia Pasquali et al.   JOURNAL OF NEPHROLOGY

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012

(2014) Jasmine Tan et al.   NEPHROLOGY

The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment

(2014) Katarina Uttervall et al.   PLoS One

Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents

(2013) M. A. Dimopoulos et al.   ANNALS OF ONCOLOGY

The Double Polymethylmethacrylate Filter (DELETE System) in the Removal of Light Chains in Chronic Dialysis Patients with Multiple Myeloma

(2013) Antonio Santoro et al.   BLOOD PURIFICATION

Polymethylmethacrylate Membrane and Serum Free Light Chain Removal: Enhancing Adsorption Properties

(2013) P. Fabbrini et al.   BLOOD PURIFICATION

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

(2013) C. Scheid et al.   HAEMATOLOGICA

High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy

(2012) Marjatta Sinisalo et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clinicopathologic Correlations in Multiple Myeloma: A Case Series of 190 Patients With Kidney Biopsies

(2012) Samih H. Nasr et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment

(2012) A. A. Chanan-Khan et al.   CLINICAL CANCER RESEARCH

Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases

(2012) N. Leung et al.   Clinical Journal of the American Society of Nephrology

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma

(2012) M A Dimopoulos et al.   LEUKEMIA

Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis

(2012) C. A. Hutchison et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Management of myeloma-associated renal dysfunction in the era of novel therapies

(2012) Mahmoud R Gaballa et al.   Expert Review of Hematology

Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury

(2011) Nils Heyne et al.   ANNALS OF HEMATOLOGY

The pathogenesis and diagnosis of acute kidney injury in multiple myeloma

(2011) Colin A. Hutchison et al.   Nature Reviews Nephrology

Renal Improvement in Myeloma with Bortezomib plus Plasma Exchange

(2011) Brian L. Burnette et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reduction of Free Immunoglobulin Light Chains Using Adsorption Properties of Hemodiafiltration with Endogenous Reinfusion

(2010) Angelo Testa et al.   BLOOD PURIFICATION

The Incidence of Major Hemorrhagic Complications After Renal Biopsies in Patients with Monoclonal Gammopathies

(2010) R. Fish et al.   Clinical Journal of the American Society of Nephrology

Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

(2010) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney

(2010) K. Basnayake et al.   JOURNAL OF CLINICAL PATHOLOGY

Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis

(2009) C. A. Hutchison et al.   Clinical Journal of the American Society of Nephrology

VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study

(2009) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study

(2009) D. J. Tsakiris et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Bortezomib-Induced Survival Signals and Genes in Human Proximal Tubular Cells

(2008) R. Sarkozi et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains

(2008) N. Leung et al.   KIDNEY INTERNATIONAL

European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial

(2008) Colin A Hutchison et al.   Trials